Can a healthy person have a positive ANA?

Yes. Low-titre ANA positivity occurs in approximately 5–15 per cent of healthy individuals, more frequently in women and older adults. Positive results without clinical features of autoimmune disease are usually not significant and do not require treatment.

Does a negative ANA rule out lupus?

A negative ANA by HEp-2 immunofluorescence has approximately 95 per cent negative predictive value for SLE and effectively excludes active untreated disease. Rare patients with anti-SSA (Ro)-positive lupus or subacute cutaneous lupus may be ANA-negative, so direct anti-Ro/La testing is warranted if clinical suspicion is high.

What is the ANA reflex and why is it done?

When the initial screen is positive, the laboratory automatically performs titre dilutions and reports the fluorescence pattern. This reflex saves a second blood draw and provides stratification — titre correlates with disease likelihood, and pattern guides which confirmatory antibodies to order next.

Should ANA be repeated to monitor disease activity?

No. ANA titre does not reliably track disease activity or flare in established lupus or other connective-tissue diseases. Monitoring should rely on clinical assessment, complement levels, anti-dsDNA (in SLE), and inflammatory markers rather than serial ANA testing.

What fluorescence patterns are reported and what do they mean?

Common patterns include homogeneous (anti-chromatin or anti-histone, seen in SLE and drug-induced lupus), speckled (anti-ENA such as Sm, RNP, SSA, SSB), nucleolar (anti-RNA polymerase or anti-fibrillarin in systemic sclerosis), and centromere (limited cutaneous systemic sclerosis). Patterns are not disease-specific but guide confirmatory testing.

Is fasting required for the ANA test?

No. The ANA test does not require fasting or any special preparation. It is ideally collected before starting corticosteroids or immunosuppressants, which can reduce antibody titres.

Can medications cause a positive ANA?

Yes. Drugs such as hydralazine, procainamide, minocycline, anti-TNF biologics, and immune checkpoint inhibitors can induce ANA positivity and drug-induced lupus. A detailed drug history is essential before attributing a positive ANA to primary autoimmune disease.

BML-AUT-012autoimmune inflammationUSA

ANA Screen, IFA, with Reflex to Titer and Pattern

The ANA screen by indirect immunofluorescence detects antinuclear antibodies, immunoglobulins against nuclear constituents that characterise systemic autoimmune rheumatic diseases. A negative result effectively rules out active untreated SLE; positive results reflex to titre and fluorescence pattern to stratify significance and guide extractable nuclear antigen testing.

Biomarkers

Blood (serum)

Sample

2–4 business days

Turnaround

Fasting

What is the ANA Screen with Reflex test?

The ANA Screen by indirect immunofluorescence is the first-line serological test for systemic lupus erythematosus and other systemic autoimmune rheumatic diseases. It is ordered when clinical features — arthralgia, rash, serositis, cytopenia, unexplained multisystem inflammation, or Raynaud phenomenon — raise suspicion for a connective-tissue disorder. Because the negative predictive value approaches 95 per cent for SLE, a negative screen effectively excludes active untreated disease, while a positive result triggers reflex titre and pattern reporting to guide further workup. The reflex design is efficient: it spares the patient a second venepuncture and the clinician the task of deciding which dilution to order upfront, and it provides both quantitative (titre) and qualitative (pattern) data to stratify significance. Low-titre positivity is common and often clinically irrelevant, so context is everything — practitioners weigh titre, pattern, and clinical pretest probability together before pursuing extractable nuclear antigen panels or subspecialty referral.

What does the ANA Screen with Reflex test measure?

ANA(Antinuclear Antibody Screen)

Range: Negative at 1:40 dilution. Positive results are reflexed to titre and fluorescence pattern.Optimal: Negative. Low-titre positivity (1:40–1:80) without clinical features is rarely significant and may be seen in healthy individuals, particularly older adults and women.qualitative (positive/negative) / titre (1:40, 1:80, 1:160, 1:320, ≥1:640)

Antinuclear antibodies are immunoglobulins directed against nuclear constituents — chromatin, ribonucleoproteins, centromere proteins, or other nuclear antigens. Their presence reflects a breakdown in immune tolerance to self-antigens and is characteristic of systemic autoimmune rheumatic diseases, though low-titre ANAs occur in healthy individuals and rise in frequency with age. Indirect immunofluorescence on HEp-2 cells is the reference method because the substrate's dividing cells express a wide range of nuclear and cytoplasmic antigens, maximising sensitivity.

The ANA is the gatekeeper test for systemic lupus erythematosus and other connective-tissue diseases. A negative screen has high negative predictive value and effectively rules out active SLE, but a positive result is non-specific — it must be interpreted by titre, pattern, clinical context, and follow-on extractable nuclear antigen serology. Titre correlates loosely with disease likelihood, and the fluorescence pattern guides selection of confirmatory antibodies.

ANA Pattern(ANA Fluorescence Pattern)

Range: Not applicable; pattern is reported only when ANA is positive.Optimal: Not applicable.qualitative (homogeneous, speckled, nucleolar, centromere, other)

The fluorescence pattern reflects the intracellular distribution of the target antigen. Homogeneous staining arises from antibodies to chromatin or histones; speckled patterns from antibodies to extractable nuclear antigens such as Sm, RNP, SSA, or SSB; nucleolar patterns from anti-RNA polymerase or anti-fibrillarin; and centromere patterns from anti-centromere antibodies. The pattern is descriptive and helps prioritise which extractable nuclear antigen or other autoantibody assays to request next.

Pattern interpretation narrows the differential and directs confirmatory testing. A homogeneous pattern is common in SLE and drug-induced lupus; speckled in SLE, Sjögren syndrome, and mixed connective-tissue disease; nucleolar in systemic sclerosis; and centromere in limited cutaneous systemic sclerosis. Patterns are not disease-specific, so clinical correlation and targeted antibody panels remain essential.

Why is the ANA Screen with Reflex test ordered?

Investigation of suspected systemic lupus erythematosus in patients with multisystem inflammation, unexplained rash, arthralgia, serositis, or cytopenia
Evaluation of Raynaud phenomenon, particularly when associated with digital ulceration, puffy hands, or other features suggesting systemic sclerosis or mixed connective-tissue disease
Work-up of unexplained inflammatory arthritis, especially in young women or when rheumatoid-factor-negative polyarthritis is present
Assessment of sicca symptoms — dry eyes and dry mouth — that may reflect primary Sjögren syndrome, where ANA is often positive alongside anti-SSA and anti-SSB
Screening in patients with idiopathic thrombocytopenia, haemolytic anaemia, or leucopenia that could represent an autoimmune process
Monitoring is not recommended; ANA titre does not reliably track disease activity, so serial testing in established disease adds little clinical value
Pre-employment, insurance, or asymptomatic screening is inappropriate because of the high rate of low-titre positivity in healthy populations

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

2–4 business days

Collection notes

Phlebotomy via Quest patient service centre; no special preparation. Ideally collected before starting corticosteroids or immunosuppressive therapy, as these can reduce antibody titres. Avoid grossly haemolysed or icteric specimens, which may interfere with fluorescence reading.

Specimen requirements

Minimum 1.0 mL serum in a serum separator tube. Stable refrigerated for up to seven days; store frozen if longer delay before analysis. Note the performing laboratory for serial comparability, as reference cut-offs and pattern nomenclature may differ between platforms.

What can affect ANA Screen with Reflex results?

elevatesAge and female sex

ANA prevalence rises with age, reaching 10–15 per cent in healthy individuals over 65, and is higher in women. Low-titre positivity in an older asymptomatic woman is often of no clinical significance.

elevatesMedications (hydralazine, procainamide, minocycline, anti-TNF biologics, checkpoint inhibitors)

Drug-induced lupus and drug-induced ANA positivity can occur with numerous medications; a careful drug history is mandatory before attributing a positive ANA to primary autoimmune disease.

elevatesChronic infections (hepatitis C, HIV, endocarditis)

Persistent antigenic stimulation can induce polyclonal B-cell activation and non-specific ANA production; screen for occult infection in the appropriate clinical setting.

elevatesMalignancy

Haematological and solid malignancies occasionally trigger autoantibody formation; consider occult neoplasm if ANA-positive with atypical features or weight loss.

variableLaboratory method and substrate

HEp-2 immunofluorescence is the reference standard and more sensitive than older substrates or multiplex bead assays; results are not directly interchangeable across methods.

variableSample quality and timing

Haemolysis or icterus can interfere with fluorescence reading; immunosuppressive treatment may reduce titre, so testing is ideally performed before starting corticosteroids or immunosuppressants.

What do ANA Screen with Reflex results mean?

Elevated

A positive ANA (titre ≥1:40) must be interpreted by titre and pattern. Titres of 1:40–1:80 are of uncertain significance and common in healthy individuals; titres ≥1:160 are more specific, and titres ≥1:640 strongly raise suspicion for systemic autoimmune disease. Homogeneous patterns suggest anti-dsDNA or anti-histone antibodies (pursue in SLE and drug-induced lupus); speckled patterns warrant anti-ENA testing (Sm, RNP, SSA, SSB); nucleolar patterns point toward systemic sclerosis and prompt anti-Scl-70 or anti-RNA polymerase III; centromere patterns indicate limited cutaneous systemic sclerosis. Clinical correlation is essential — a high-titre ANA in a patient with malar rash and arthritis is highly significant, while the same titre in an asymptomatic individual may be incidental.

Normal

A negative ANA at 1:40 dilution has approximately 95 per cent negative predictive value for SLE and effectively excludes the diagnosis in an untreated patient. Rare patients with anti-SSA (Ro)-positive lupus or subacute cutaneous lupus may be ANA-negative by standard IFA, so if clinical suspicion is high, request anti-ENA or anti-Ro/La directly. A negative screen also makes mixed connective-tissue disease unlikely but does not exclude seronegative inflammatory arthritis or organ-specific autoimmune conditions.

Reduced

Not applicable; ANA is reported as negative or positive with titre, not as a continuously variable concentration.

Note: ANA is a screening test, not a diagnosis. Positive results require clinical correlation, and low-titre positivity is prevalent in healthy populations. Do not repeat ANA serially to monitor disease activity; it is a poor surrogate for flare. Always interpret in conjunction with extractable nuclear antigen serology and clinical classification criteria (ACR/EULAR SLE, ACR/EULAR systemic sclerosis). The reflex titre and pattern are performed automatically by the laboratory when the screen is positive, so practitioners receive actionable stratification without ordering each step separately.

Frequently asked questions

A positive ANA indicates the presence of antinuclear antibodies but is not a diagnosis. It must be interpreted by titre, fluorescence pattern, and clinical context. Low titres (1:40–1:80) are common in healthy individuals, while high titres (≥1:160) raise suspicion for systemic autoimmune disease and warrant further antibody testing and clinical correlation.

How to access the ANA Screen with Reflex test

The ANA Screen with Reflex reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Pisetsky DS, et al. ANA as an entry criterion for the classification of SLE. Autoimmun Rev. (2019)
American College of Rheumatology position statement: methodology of testing for antinuclear antibodies. Arthritis Care Res (Hoboken). (2019)
Aringer M, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. (2019)
Agmon-Levin N, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. (2014)
Satoh M, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. (2017)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.